Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos (t) ide
analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to …

The management of chronic hepatitis B currently rests with long‐term therapy using oral
nucleoside analogs. The major limitation of long‐term therapy is antiviral resistance …

The 2009 update of the American Association for the Study of Liver Diseases (AASLD)
Practice Guidelines for Management of Chronic Hepatitis B are now posted online at www …

BACKGROUND & AIMS: Patients with hepatitis B e antigen (HBeAg)–negative chronic
hepatitis B treated with peginterferon alfa-2a with or without lamivudine achieve significantly …

Abstract Within 25 years after zidovudine (3′‐azido‐2′, 3′‐dideoxythymidine, AZT) was
first described as an inhibitor of HIV replication, 25 anti‐HIV drugs have been formally …

HBV replicates through reverse transcription of an RNA intermediate; the inherent lack of
proofreading causes a high mutation frequency. Mutations in the precore and core promoter …

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most frequent
viral infections in humans, and represent a major global public health problem. HBV‐and …

During the natural history of chronic hepatitis B virus (HBV) infection, the loss of serum
hepatitis B e antigen (HBeAg) and the development of anti-HBe antibodies (HBeAg …

BACKGROUND & AIMS: In the last decade, significant progress has been made in the
treatment of liver disease associated with chronic hepatitis, especially in patients infected …

Asia comprises more than 40 countries encompassing a wide geographic area with a very
large population. Many of these countries have low-income economies together with high …